338 results on '"Nosaki, Kaname"'
Search Results
52. TRUST-II: A global phase II study for taletrectinib in ROS1 fusion–positive lung cancer and other solid tumors.
53. KRAS G12V mutation as an acquired resistance mechanism after treatment with dabrafenib and trametinib in non-small cell lung cancer harbouring the BRAF V600E mutation: a case report
54. Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)
55. The Impact of Tertiary Lymphoid Structures on Clinicopathological, Genetic and Gene Expression Characteristics in Lung Adenocarcinoma
56. Large-Scale Clinico-Genomic Profile of Non-Small Cell Lung Cancer with KRAS G12C: Results from LC-SCRUM-Asia Study
57. A Phase II Study (WJOG12819L) to Assess the Efficacy of Osimertinib in Patients with EGFR Mutation-Positive NSCLC in Whom Systemic Disease (T790M-Negative) Progressed after Treatment with First- Or Second-Generation EGFR TKIS and Platinum-Based Chemotherapy
58. PS-3 - Japan subset of Phase III study KEYNOTE-024: Pembrolizumab for PD-L1 TPS > =50%, treatment-naïve NSCLC
59. The mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance
60. Are Anthracycline-Based Regimens Truly Indicated To Be the Standard Chemotherapy Regimen for Thymic Carcinoma?
61. A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L)
62. ICI Monotherapy or Combination Therapy in the Treatment of NSCLC: How to Choose Among Multiple Options
63. First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset*
64. Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non–small-cell Lung Cancer Exhibiting Resistance to Ceritinib
65. Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours
66. Comparison of the efficiency of endobronchial ultrasound-guided transbronchial needle aspiration using a 22G needle versus 25G needle for the diagnosis of lymph node metastasis in patients with lung cancer: a prospective randomized, crossover study
67. P30-3 Clinical experience of tumour lysis syndrome in patients with extensive disease small cell lung cancer
68. First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset
69. Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib
70. The 2020 Edition of the Clinical Guidelines for Lung Cancer: Challenges and Future Perspectives
71. Optimal next-generation sequencing (NGS) panel for estimating tumor mutation burden (TMB) and its clinical implication for non-small cell lung cancer (NSCLC).
72. Clinico-pathological and genomic features of NRAS- or HRAS-mutated non-small cell lung cancer (NSCLC) identified in large-scale genomic screening project (LC-SCRUM-Asia).
73. Impact of rapid multigene assays with short turnaround time (TAT) on the development of precision medicine for non-small cell lung cancer (NSCLC).
74. Impact of concomitant medication on clinical outcomes in patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study
75. The role of comprehensive analysis with circulating tumor DNA in advanced non‐small cell lung cancer patients considered for osimertinib treatment
76. Classification and Treatment of Oligometastatic Disease in Non-Small-Cell Lung Cancer
77. P3-1-17 - Management of toxicities and dose reduction/interruption of afatinib for EGFR mutated non-small cell lung cancer
78. P1-1-20 - Systemic chemotherapy for pulmonary pleomorphic carcinoma
79. LKB1 Mutations Frequently Detected in Mucinous Bronchioloalveolar Carcinoma
80. Retracted: First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset
81. Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer
82. Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101)
83. Therapeutic impact of mutation subtypes and concomitant STK11 mutations in KRAS–mutated non-small cell lung cancer (NSCLC): A result of nationwide genomic screening project (LC-SCRUM-Japan).
84. Genetic profiling and the response to RET inhibitors in RET fusion positive non-small cell lung cancer (NSCLC) identified by international genomic screening project (LC-SCRUM-Asia).
85. Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab
86. Short progression‐free survival of ALK inhibitors sensitive to secondary mutations in ALK‐positive NSCLC patients
87. Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA
88. Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer
89. First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset.
90. Exploration of resistance mechanisms for epidermal growth factor receptor‐tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next‐generation sequencing
91. The Treatment Strategy for ALK-positive Non-small-cell Lung Carcinoma
92. Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study
93. A case of different EGFR mutations in surgically resected synchronous triple lung cancer
94. A typical carcinoid tumor of the lung presenting with pure persistent ground-glass opacity on high-resolution computed tomography: a case report
95. Japan subset of Phase III study KEYNOTE-024: Pembrolizumab for PD-L1 TPS > =50%, treatment-naïve NSCLC
96. Surgical resection of a well-differentiated inflammatory liposarcoma of the middle mediastinum: a case report
97. Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non‐small‐cell lung cancer
98. Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non–small cell lung cancer harboring EGFR mutations
99. A nationwide genomic screening project for small cell lung cancer in Japan (LC-SCRUM-Japan).
100. Real-world data on treatment patterns and survival among ALK+ NSCLC patients in Japan.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.